Virax Return On Equity from 2010 to 2024

VRAX Stock  USD 1.94  0.20  9.35%   
Virax Biolabs Return On Equity yearly trend continues to be fairly stable with very little volatility. Return On Equity is likely to outpace its year average in 2024. Return On Equity is a measure of the profitability of Virax Biolabs Group in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(1.25)
Current Value
(1.19)
Quarterly Volatility
0.8336555
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 8.96, Dividend Yield of 0.0 or PTB Ratio of 0.29. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' Return On Equity Growth Pattern

Below is the plot of the Return On Equity of Virax Biolabs Group over the last few years. Return on Equity is the amount of Virax Biolabs Group net income returned as a percentage of Virax Biolabs equity. Return on equity measures Virax Biolabs profitability by revealing how much profit Virax Biolabs Group generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Virax Biolabs' Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -0.9610 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

Virax Return On Equity Regression Statistics

Arithmetic Mean0.49
Coefficient Of Variation169.25
Mean Deviation0.60
Median0.76
Standard Deviation0.83
Sample Variance0.69
Range3.0081
R-Value(0.53)
Mean Square Error0.54
R-Squared0.28
Significance0.04
Slope(0.1)
Total Sum of Squares9.73

Virax Return On Equity History

2024 -1.19
2023 -1.25
2022 -0.6
2021 1.75
2020 1.09

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Return On Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Equity(1.25)(1.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.